Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Drug Insight: metastatic colorectal cancer—oral fluoropyrimidines and new perspectives in the adjuvant setting

Nature Clinical Practice Oncology volume 2, pages 578–587 (2005)Cite this article

Abstract

Capecitabine and uracil/ftorafur (UFT) are prodrugs of 5-fluorouracil (5-FU) that can be administered orally. Both drugs have been shown to be as effective as bolus 5-FU and folinic acid (FA), both as adjuvant treatment, and for the treatment of metastatic colorectal cancer. However, as the addition of oxaliplatin to 5-FU has been shown to improve disease-free survival in adjuvant therapy, oxaliplatin/5-FU is currently regarded as the standard adjuvant treatment, rather than fluoropyrimidine monotherapy. For the treatment of metastatic colorectal cancer, improved response rates and prolonged survival have been reported when irinotecan or oxaliplatin was added to 5-FU/FA; a further increase in efficacy was shown when bevacizumab, an antibody to vascular endothelial growth factor, was added to chemotherapy. Studies investigating the substitution of infusional 5-FU with oral compounds in combination therapy (e.g. FOLFOX versus capecitabine/oxaliplatin) are ongoing, but preliminary results in metastatic patients advise caution because of increased toxicity when used with irinotecan, and statistically non-significant trends of a decreased efficacy when used with oxaliplatin. Therefore, the combined use of oral 5-FU prodrugs plus irinotecan or oxaliplatin is not recommended at present. Oral 5-FU prodrugs, however, offer a convenient and less toxic treatment option in adjuvant treatment and in the treatment of advanced colorectal carcinoma in patients who do not want an intensified regimen, those that have contraindications for implanted venous access devices, and those who are not candidates for a combination therapy with irinotecan and oxaliplatin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Simplified pathway of 5-fluorouracil and oral fluoropyrimidines.

Similar content being viewed by others

References

  1. Simmonds PC. (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321: 531–535

    Article  CAS  Google Scholar 

  2. Köhne CH et al. (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23: 4856–4865

    Article  Google Scholar 

  3. Douillard JY et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041–1047

    Article  CAS  Google Scholar 

  4. de Gramont A et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938–2947

    Article  CAS  Google Scholar 

  5. Giacchetti S et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136–147

    Article  CAS  Google Scholar 

  6. Grothey A et al. (2002) Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21: a129

    Google Scholar 

  7. Folprecht G et al. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16: 1311–1319

    Article  CAS  Google Scholar 

  8. Cunningham D et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

    Article  CAS  Google Scholar 

  9. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

    Article  CAS  Google Scholar 

  10. Kabbinavar FF et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697–3705

    Article  CAS  Google Scholar 

  11. Giantonio B et al. (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. [abstract #2] Proc Am Soc Clin Oncol 23

  12. Saltz LB et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905–914

    Article  CAS  Google Scholar 

  13. Goldberg RM et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23–30

    Article  CAS  Google Scholar 

  14. [No authors listed] (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10: 896–903

  15. Thirion P et al. (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22: 3766–3775

    Article  CAS  Google Scholar 

  16. [No authors listed] (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16: 301–308

  17. [No authors listed] (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16: 3537–3541

  18. de Gramont A et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808–815

    Article  CAS  Google Scholar 

  19. Köhne CH et al. (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21: 3721–3728

    Article  Google Scholar 

  20. Rothenberg M et al. (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801–3807

    Article  CAS  Google Scholar 

  21. Miwa M et al. (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274–1281

    Article  CAS  Google Scholar 

  22. Mackean M et al. (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16: 2977–2985

    Article  CAS  Google Scholar 

  23. Shirasaka T et al. (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548–557

    Article  CAS  Google Scholar 

  24. Hoff PM et al. (1998) UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 9: 479–490

    CAS  PubMed  Google Scholar 

  25. Van Cutsem E et al. (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18: 1337–1345

    Article  CAS  Google Scholar 

  26. Schilsky RL et al. (2002) Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 20: 1519–1526

    Article  CAS  Google Scholar 

  27. Van Cutsem E et al. (2001) International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). [abstract] Proc Am Soc Clin Oncol 20: a131

    Google Scholar 

  28. Van Cutsem E et al. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097–4106

    Article  CAS  Google Scholar 

  29. Hoff PM et al. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282–2292

    Article  CAS  Google Scholar 

  30. Cockcroft DW et al. (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41

    Article  CAS  Google Scholar 

  31. Cassidy J et al. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566–575

    Article  CAS  Google Scholar 

  32. Bertolini A et al. (2001) Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 87: 200–206

    Article  CAS  Google Scholar 

  33. Carmichael J et al. (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617–3627

    Article  CAS  Google Scholar 

  34. Douillard JY et al. (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605–3616

    Article  CAS  Google Scholar 

  35. Twelves C et al. (2001) Capecitabine (Xeloda) improves medical resource use compared with 5- fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37: 597–604

    Article  CAS  Google Scholar 

  36. Borner MM et al. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349–358

    Article  CAS  Google Scholar 

  37. Liu G et al. (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110–115

    Article  CAS  Google Scholar 

  38. Seymour M (2004) Optimizing the use and sequencing of fluorouracil, irinotecan and oxaliplatin in advanced colorectal cancer (ACRC): The UK MRC FOCUS (CR08) trial [abstract]. Ann Oncol 15 (Suppl 3): 5IN

    Google Scholar 

  39. Grothey A et al. (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214

    Article  CAS  Google Scholar 

  40. Grothey A et al. (2003) Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 22: 255

    Google Scholar 

  41. Tewes M et al. (2003) Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol 14: 1442–448

    Article  CAS  Google Scholar 

  42. Borner MM et al. (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16: 282–288

    Article  CAS  Google Scholar 

  43. Köhne CH et al. (2005) Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/− celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. [abstract #3525] Proc Am Soc Clin Oncol 23

  44. Cassidy J et al. (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084–2091

    Article  CAS  Google Scholar 

  45. Scheithauer W et al. (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21: 1307–1312

    Article  CAS  Google Scholar 

  46. Arkenau H et al. (2005) Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. [abstract #3507] Proc Am Soc Clin Oncol 23

  47. Hochster HS et al. (2005) Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. [abstract #3515] Proc Am Soc Clin Oncol 23

  48. Fernando N et al. (2005) A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. [abstract #3556] Proc Am Soc Clin Oncol 23

  49. Moertel CG et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352–358

    Article  CAS  Google Scholar 

  50. [No authors listed] (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345: 939–944

  51. Wolmark N et al. (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from national surgical adjuvant breast and bowel project C-04. J Clin Oncol 17: 3553–3559

    Article  CAS  Google Scholar 

  52. Haller DG et al. (1998) Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five-year final report of INT-0089. [abstract] Proc Am Soc Clin Oncol 16: a256

    Google Scholar 

  53. Saini A et al. (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88: 1859–1865

    Article  CAS  Google Scholar 

  54. Andre T et al. (2002) Phase III trial (GERCOR C96.1) comparing bimonthly LV5FU2 to monthly 5FU-leucoverin high dose (LV hd) in patients with Dukes B2 and C colon cancer. [abstract] Proc Am Soc Clin Oncol 21: a133

    Google Scholar 

  55. Poplin EA et al. (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819–1825

    Article  CAS  Google Scholar 

  56. Twelves C et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696–2704

    Article  CAS  Google Scholar 

  57. Wolmark N et al. (2004) A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06. J Clin Oncol 22 (Suppl): s247

    Google Scholar 

  58. Andre T et al. (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351

    Article  CAS  Google Scholar 

  59. Wolmark N et al. (2005) A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. [abstract #LBA3500] Proc Am Soc Clin Oncol 23

  60. Saltz LB et al. (2004) Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). [abstract #3500] J Clin Oncol 22

  61. Van Cutsem E et al. (2005) Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). [abstract #8] Proc Am Soc Clin Oncol 23

  62. Ychou M et al. (2005) A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). [abstract #3502] Proc Am Soc Clin Oncol 23

  63. Sargent DJ et al. (2004) Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol 22: 3502

    Article  Google Scholar 

  64. Bajetta E et al. (2004) Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100: 279–28755

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. medical oncologist at the University Hospital of Dresden, Germany

    Gunnar Folprecht

  2. Head of the Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany

    Claus-Henning Köhne

Authors
  1. Gunnar Folprecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claus-Henning Köhne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gunnar Folprecht.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Folprecht, G., Köhne, CH. Drug Insight: metastatic colorectal cancer—oral fluoropyrimidines and new perspectives in the adjuvant setting. Nat Rev Clin Oncol 2, 578–587 (2005). https://doi.org/10.1038/ncponc0353

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0353

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing